Cite
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
MLA
Fisher, Richard I., et al. “Multicenter Phase II Study of Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 24, no. 30, Oct. 2006, pp. 4867–74. EBSCOhost, https://doi.org/10.1200/JCO.2006.07.9665.
APA
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Stadtmauer, E. A., O’Connor, O. A., Shi, H., Boral, A. L., & Goy, A. (2006). Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 24(30), 4867–4874. https://doi.org/10.1200/JCO.2006.07.9665
Chicago
Fisher, Richard I, Steven H Bernstein, Brad S Kahl, Benjamin Djulbegovic, Michael J Robertson, Sven de Vos, Elliot Epner, et al. 2006. “Multicenter Phase II Study of Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 24 (30): 4867–74. doi:10.1200/JCO.2006.07.9665.